GB9520150D0 - New imidazole derivatives - Google Patents

New imidazole derivatives

Info

Publication number
GB9520150D0
GB9520150D0 GBGB9520150.5A GB9520150A GB9520150D0 GB 9520150 D0 GB9520150 D0 GB 9520150D0 GB 9520150 A GB9520150 A GB 9520150A GB 9520150 D0 GB9520150 D0 GB 9520150D0
Authority
GB
United Kingdom
Prior art keywords
alkyl
hydrogen
different
alkoxy
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GBGB9520150.5A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orion Oyj
Original Assignee
Orion Yhtyma Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Yhtyma Oy filed Critical Orion Yhtyma Oy
Priority to GBGB9520150.5A priority Critical patent/GB9520150D0/en
Publication of GB9520150D0 publication Critical patent/GB9520150D0/en
Priority to SK439-98A priority patent/SK283542B6/sk
Priority to RO98-00825A priority patent/RO120409B1/ro
Priority to JP51399497A priority patent/JP4129891B2/ja
Priority to NZ319169A priority patent/NZ319169A/xx
Priority to DE69626862T priority patent/DE69626862T2/de
Priority to DK96932609T priority patent/DK0888309T3/da
Priority to EP96932609A priority patent/EP0888309B1/en
Priority to AU71327/96A priority patent/AU708002B2/en
Priority to EE9800101A priority patent/EE04436B1/xx
Priority to CA002231535A priority patent/CA2231535C/en
Priority to AT96932609T priority patent/ATE234819T1/de
Priority to CZ19981018A priority patent/CZ291576B6/cs
Priority to KR1019980702490A priority patent/KR19990064013A/ko
Priority to PT96932609T priority patent/PT888309E/pt
Priority to HU9802927A priority patent/HU224197B1/hu
Priority to PCT/FI1996/000518 priority patent/WO1997012874A1/en
Priority to PL96328167A priority patent/PL189110B1/pl
Priority to UA98031588A priority patent/UA49847C2/uk
Priority to IL12372196A priority patent/IL123721A/en
Priority to CN96197438A priority patent/CN1068592C/zh
Priority to US09/051,151 priority patent/US6313311B1/en
Priority to SI9620111A priority patent/SI9620111B/sl
Priority to RU98108027/04A priority patent/RU2188194C2/ru
Priority to ES96932609T priority patent/ES2195013T3/es
Priority to BG102324A priority patent/BG63916B1/bg
Priority to LVP-98-61A priority patent/LV12108B/en
Priority to NO19981496A priority patent/NO311024B1/no
Priority to LT98-057A priority patent/LT4460B/lt
Priority to HK99100180A priority patent/HK1014951A1/xx
Priority to US09/904,836 priority patent/US6479530B2/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, ***e
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Anesthesiology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epoxy Resins (AREA)
GBGB9520150.5A 1995-10-03 1995-10-03 New imidazole derivatives Pending GB9520150D0 (en)

Priority Applications (31)

Application Number Priority Date Filing Date Title
GBGB9520150.5A GB9520150D0 (en) 1995-10-03 1995-10-03 New imidazole derivatives
ES96932609T ES2195013T3 (es) 1995-10-03 1996-10-02 Derivados de imidazol que tienen afinidad para la actividad de receptores alfa2.
PT96932609T PT888309E (pt) 1995-10-03 1996-10-02 Derivados de imidazole que possuem afinidade para actividade de receptores de alfa2
PL96328167A PL189110B1 (pl) 1995-10-03 1996-10-02 Pochodna imidazolu, kompozycja farmaceutyczna zawierająca pochodną imidazolu i zastosowanie pochodnej imidazolu
HU9802927A HU224197B1 (hu) 1995-10-03 1996-10-02 Alfa2-receptorokra ható imidazolszármazékok
NZ319169A NZ319169A (en) 1995-10-03 1996-10-02 Imidazole derivatives as <alpha>-2 agonists
DE69626862T DE69626862T2 (de) 1995-10-03 1996-10-02 Imidazolderivate mit alpha2-rezeptor aktivität
DK96932609T DK0888309T3 (da) 1995-10-03 1996-10-02 Imidazolderivater med affinitet for alpha-2-receptor aktivitet
EP96932609A EP0888309B1 (en) 1995-10-03 1996-10-02 Imidazole derivatives having affinity for alpha2 receptors activity
AU71327/96A AU708002B2 (en) 1995-10-03 1996-10-02 Imidazole derivatives having affinity for alpha2 receptors activity
EE9800101A EE04436B1 (et) 1995-10-03 1996-10-02 Alfa2 retseptorite aktiivsuse suhtes afiinsed imidasooli derivaadid
CA002231535A CA2231535C (en) 1995-10-03 1996-10-02 Imidazole derivatives having affinity for alpha2 receptors activity
AT96932609T ATE234819T1 (de) 1995-10-03 1996-10-02 Imidazolderivate mit alpha2-rezeptor aktivität
CZ19981018A CZ291576B6 (cs) 1995-10-03 1996-10-02 Derivát imidazolu afinitní k alfa2 receptorům, farmaceuticky přijatelný přípravek jej obsahující a jeho použití
KR1019980702490A KR19990064013A (ko) 1995-10-03 1996-10-02 알파 2 받게 활성에 친화력을 갖는 이미다졸 유도체
SK439-98A SK283542B6 (sk) 1995-10-03 1996-10-02 Derivát imidazolu, farmaceutický prostriedok s jeho obsahom a jeho použitie
JP51399497A JP4129891B2 (ja) 1995-10-03 1996-10-02 α２受容体活性に親和性を有するイミダゾール誘導体
PCT/FI1996/000518 WO1997012874A1 (en) 1995-10-03 1996-10-02 Imidazole derivatives having affinity for alpha2 receptors activity
RU98108027/04A RU2188194C2 (ru) 1995-10-03 1996-10-02 Производные имидазола и фармацевтически приемлемая композиция
UA98031588A UA49847C2 (uk) 1995-10-03 1996-10-02 ПОХІДНІ ІМІДАЗОЛУ, ЩО МАЮТЬ СПОРІДНЕНІСТЬ ДО АКТИВНОСТІ <font face="Symbol">a</font>2-РЕЦЕПТОРІВ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ТА СПОСІБ ЛІКУВАННЯ
IL12372196A IL123721A (en) 1995-10-03 1996-10-02 History of imidazole with affinities for alpha 2 receptors, methods for their preparation and pharmaceutical preparations containing them
CN96197438A CN1068592C (zh) 1995-10-03 1996-10-02 具有α2受体亲合活性的咪唑衍生物
US09/051,151 US6313311B1 (en) 1995-10-03 1996-10-02 Imidazole derivatives having affinity for alpha2 receptors
SI9620111A SI9620111B (en) 1995-10-03 1996-10-02 Imidazole derivatives having affinity for alpha2 receptors activity
RO98-00825A RO120409B1 (ro) 1995-10-03 1996-10-02 Derivaţi de imidazol, compoziţie farmaceutică a acestora şi utilizarea lor
BG102324A BG63916B1 (bg) 1995-10-03 1998-03-12 Имидазолови производни с афинитет към активносттана алфа 2 рецептори
LVP-98-61A LV12108B (en) 1995-10-03 1998-03-31 IMPORTANT DERIVATIVES FOR ALFA-2 RECEPTORS
NO19981496A NO311024B1 (no) 1995-10-03 1998-04-02 Imidazolderivater med affinitet for <alfa> 2- reseptoraktivitet, preparat inneholdende det, samt anvendelse avderivatet
LT98-057A LT4460B (lt) 1995-10-03 1998-04-22 Imidazolo dariniai, giminingi alfa2 receptoriams
HK99100180A HK1014951A1 (en) 1995-10-03 1999-01-14 Imidazole derivatives having affinity for alpha2 receptors activity
US09/904,836 US6479530B2 (en) 1995-10-03 2001-07-16 Imidazole derivatives having affinity for α2 receptors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9520150.5A GB9520150D0 (en) 1995-10-03 1995-10-03 New imidazole derivatives

Publications (1)

Publication Number Publication Date
GB9520150D0 true GB9520150D0 (en) 1995-12-06

Family

ID=10781676

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9520150.5A Pending GB9520150D0 (en) 1995-10-03 1995-10-03 New imidazole derivatives

Country Status (30)

Country Link
US (2) US6313311B1 (no)
EP (1) EP0888309B1 (no)
JP (1) JP4129891B2 (no)
KR (1) KR19990064013A (no)
CN (1) CN1068592C (no)
AT (1) ATE234819T1 (no)
AU (1) AU708002B2 (no)
BG (1) BG63916B1 (no)
CA (1) CA2231535C (no)
CZ (1) CZ291576B6 (no)
DE (1) DE69626862T2 (no)
DK (1) DK0888309T3 (no)
EE (1) EE04436B1 (no)
ES (1) ES2195013T3 (no)
GB (1) GB9520150D0 (no)
HK (1) HK1014951A1 (no)
HU (1) HU224197B1 (no)
IL (1) IL123721A (no)
LT (1) LT4460B (no)
LV (1) LV12108B (no)
NO (1) NO311024B1 (no)
NZ (1) NZ319169A (no)
PL (1) PL189110B1 (no)
PT (1) PT888309E (no)
RO (1) RO120409B1 (no)
RU (1) RU2188194C2 (no)
SI (1) SI9620111B (no)
SK (1) SK283542B6 (no)
UA (1) UA49847C2 (no)
WO (1) WO1997012874A1 (no)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA981080B (en) * 1997-02-11 1998-08-12 Warner Lambert Co Bicyclic inhibitors of protein farnesyl transferase
US6329369B1 (en) 1997-12-04 2001-12-11 Allergan Sales, Inc. Methods of treating pain and other conditions
AU2002254265B2 (en) * 1997-12-04 2008-05-15 Allergan, Inc. Imidiazole derivatives and their use as agonists selective at alpha 2B or 2B/2C adrenergic receptors
US6841684B2 (en) * 1997-12-04 2005-01-11 Allergan, Inc. Imidiazoles having reduced side effects
EP1036065B1 (en) * 1997-12-04 2004-05-12 Allergan, Inc. Substituted imidazole derivatives having agonist-like activity at alpha 2b or 2b/2c adrenergic receptors
EP1117399B1 (en) * 1998-09-28 2005-02-09 Orion Corporation Use of 3-(1h-imidazol-4-ylmethyl)-indan-5-ol in the manufacture of a medicament for intraspinal, intrathecal or epidural administration
TWI283669B (en) * 1999-06-10 2007-07-11 Allergan Inc Compounds and method of treatment having agonist-like activity selective at alpha 2B or 2B/2C adrenergic receptors
WO2001000192A2 (en) * 1999-06-25 2001-01-04 Orion Corporation Method of administering an imidazole derivative to obtain analgesia
AU778522B2 (en) * 1999-10-29 2004-12-09 Orion Corporation Treatment or prevention of hypotension and shock
US6388090B2 (en) 2000-01-14 2002-05-14 Orion Corporation Imidazole derivatives
FI20000073A0 (fi) * 2000-01-14 2000-01-14 Orion Yhtymae Oy Uusia imidatsolijohdannaisia
JP2003532712A (ja) * 2000-05-08 2003-11-05 オリオン コーポレーション α２アドレナリン作用活性を有する新規な多環式インダニルイミダゾール
TW200930291A (en) 2002-04-29 2009-07-16 Bayer Cropscience Ag Pesticidal heterocycles
FR2839719B1 (fr) * 2002-05-16 2004-08-06 Pf Medicament Nouveaux composes imidazoliques, leur procede de preparation et leur utilisation a titre de medicaments
FI20022159A0 (fi) * 2002-12-05 2002-12-05 Orion Corp Uusia farmaseuttisia yhdisteitä
DE102004035322A1 (de) * 2004-07-21 2006-02-16 Universität des Saarlandes Selektive Hemmstoffe humaner Corticoidsynthasen
ATE517883T1 (de) 2005-08-25 2011-08-15 Schering Corp Imidazolderivate als funktionelle selektive agonisten des alpha2c-adrenorezeptors
US7700592B2 (en) 2005-08-25 2010-04-20 Schering Corporation α2C adrenoreceptor agonists
JP2009506051A (ja) 2005-08-25 2009-02-12 シェーリング コーポレイション α２Ｃアドレナリン受容体アゴニスト
EP1981499A1 (en) * 2006-01-27 2008-10-22 F.Hoffmann-La Roche Ag Use of 2-imidazoles for the treatment of cns disorders
ES2381589T3 (es) 2006-10-19 2012-05-29 F. Hoffmann-La Roche Ag Aminometil-4-imidazoles
MX2009004617A (es) 2006-11-02 2009-05-22 Hoffmann La Roche 2-imidazoles sustituidos como moduladores de los receptores asociados con trazas de amina.
CN101535298A (zh) * 2006-11-16 2009-09-16 弗·哈夫曼-拉罗切有限公司 取代的4-咪唑类化合物
KR101189348B1 (ko) 2006-12-13 2012-10-09 에프. 호프만-라 로슈 아게 미량 아민 결합 수용체(ｔａａｒ)에 대한 리간드로서의 신규한 2-이미다졸
US20080146523A1 (en) 2006-12-18 2008-06-19 Guido Galley Imidazole derivatives
ES2510546T3 (es) 2007-02-02 2014-10-21 F. Hoffmann-La Roche Ag Nuevas 2-aminooxazolinas como ligandos TAAR1 para trastornos del SNC
US8017642B2 (en) 2007-02-13 2011-09-13 Schering Corporation Functionally selective ALPHA2C adrenoreceptor agonists
ATE530547T1 (de) 2007-02-13 2011-11-15 Schering Corp Derivate und analoge von chroman als funktionell selektive alpha2c-adrenorezeptor-agonisten
CA2678036A1 (en) 2007-02-13 2008-08-21 Schering Corporation Functionally selective alpha2c adrenoreceptor agonists
ES2525229T3 (es) 2007-02-15 2014-12-19 F. Hoffmann-La Roche Ag 2-aminooxazolinas como ligandos de TAAR1
CN101687812A (zh) 2007-07-02 2010-03-31 弗·哈夫曼-拉罗切有限公司 对痕量胺相关受体(taar)具有良好亲和性的2-咪唑啉化合物
CN101687811A (zh) 2007-07-03 2010-03-31 弗·哈夫曼-拉罗切有限公司 4-咪唑啉类及其作为抗抑郁剂的应用
WO2009016048A1 (en) 2007-07-27 2009-02-05 F. Hoffmann-La Roche Ag 2-azetidinemethaneamines and 2-pyrrolidinemethaneamines as taar-ligands
CN101784515A (zh) 2007-08-03 2010-07-21 弗·哈夫曼-拉罗切有限公司 作为taar1配体的吡啶甲酰胺和苯甲酰胺衍生物
WO2009105504A2 (en) 2008-02-21 2009-08-27 Schering Corporation Functionally selective alpha2c adrenoreceptor agonists
US8242153B2 (en) 2008-07-24 2012-08-14 Hoffmann-La Roche Inc. 4,5-dihydro-oxazol-2YL derivatives
AR073628A1 (es) 2008-10-07 2010-11-17 Schering Corp Analogos de biaril espiroaminooxazolina y espiroaminodiazolina moduladores de receptores adrenergicos alfa2c, composiciones farmaceuticas que los comprenden y uso de los mismos en rinitis alergica,trastornos cardiacos y otras enfermedades
CA2762107A1 (en) 2009-05-15 2010-11-18 Recro Pharma, Inc. Sublingual dexmedetomidine compositions and methods of use thereof
US8354441B2 (en) 2009-11-11 2013-01-15 Hoffmann-La Roche Inc. Oxazoline derivatives
US9452980B2 (en) 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
US8673950B2 (en) 2010-11-02 2014-03-18 Hoffmann-Laroche Inc. Dihydrooxazol-2-amine derivatives
US8802673B2 (en) 2011-03-24 2014-08-12 Hoffmann-La Roche Inc Heterocyclic amine derivatives
US9073911B2 (en) * 2011-06-09 2015-07-07 Hoffmann-La Roche Inc. Pyrazole derivatives
US9029370B2 (en) 2011-06-10 2015-05-12 Hoffmann-La Roche Inc. Substituted benzamide derivatives
RU2692245C2 (ru) 2011-12-11 2019-06-24 Рекро Фарма, Инк. Интраназальные композиции дексмедетомидина и способы их применения
CA2856204A1 (en) * 2012-01-12 2013-07-18 F. Hoffmann-La Roche Ag Heterocyclic derivatives as trace amine associated receptors (taars)
KR101706486B1 (ko) 2012-09-14 2017-02-13 에프. 호프만-라 로슈 아게 우울증, 당뇨병 및 파킨슨병과 같은 몇가지 장애의 치료에 사용하기 위한 taar 조절제로서의 피라졸 카복스아마이드 유도체
WO2014041106A1 (en) 2012-09-17 2014-03-20 F. Hoffmann-La Roche Ag Triazole carboxamide derivatives
WO2015165085A1 (en) 2014-04-30 2015-11-05 F.Hoffmann-La Roche Ag Morpholin-pyridine derivatives
CA2953040A1 (en) 2014-08-27 2016-03-03 F. Hoffmann-La Roche Ag Substituted pyrazino[2,1-a]isoquinoline derivatives for the treatment of cns disorders
WO2016030310A1 (en) 2014-08-27 2016-03-03 F. Hoffmann-La Roche Ag Substituted azetidine derivatives as taar ligands
PL3430010T3 (pl) 2016-03-17 2020-11-16 F. Hoffmann-La Roche Ag Pochodna 5-etylo-4-metylopirazolo-3-karboksyamidu wykazująca aktywność jako agonista taar

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3636002A (en) * 1969-12-15 1972-01-18 Janssen Pharmaceutica Nv 1-(2-halobenzyloxy-1-indanyl)-imidazoles
ES523609A0 (es) * 1982-07-05 1985-03-01 Erba Farmitalia Procedimiento para preparar derivados n-imidazolilicos de compuestos biciclicos.
US4634705A (en) * 1984-06-06 1987-01-06 Abbott Laboratories Adrenergic amidines
US4659730A (en) * 1984-06-18 1987-04-21 Eli Lilly And Company Aromatase inhibiting imidazole derivatives
GB2167408B (en) * 1984-11-23 1988-05-25 Farmos Oy Substituted imidazole derivatives and their preparation and use
FI81092C (fi) * 1986-05-15 1990-09-10 Farmos Oy Foerfarande foer framstaellning av terapeutiskt aktiva 4(5)-(2,3-dihydro-1h-inden-2-yl)-imidazolderivat.
US4878940A (en) * 1987-04-02 1989-11-07 Janssen Pharmaceutica N.V. Herbicidal 1,5-substituted 1H-imidazoles
IL91542A0 (en) * 1988-10-06 1990-04-29 Erba Carlo Spa N-imidazolyl-and n-imidazolyl-methyl derivatives of substituted bicyclic compounds,their preparation and pharmaceutical compositions containing them
GB9127050D0 (en) * 1991-12-20 1992-02-19 Orion Yhtymae Oy Substituted imidazole derivatives and their preparation and use
GB9425211D0 (en) 1994-12-14 1995-02-15 Ucb Sa Substituted 1H-imidazoles
US6388090B2 (en) * 2000-01-14 2002-05-14 Orion Corporation Imidazole derivatives

Also Published As

Publication number Publication date
PT888309E (pt) 2003-07-31
CZ101898A3 (cs) 1998-09-16
HUP9802927A3 (en) 2003-02-28
ATE234819T1 (de) 2003-04-15
JP4129891B2 (ja) 2008-08-06
HU224197B1 (hu) 2005-06-28
DE69626862T2 (de) 2003-12-24
NZ319169A (en) 1999-07-29
LT4460B (lt) 1999-02-25
IL123721A (en) 2004-07-25
AU708002B2 (en) 1999-07-29
CA2231535C (en) 2005-09-20
CN1068592C (zh) 2001-07-18
SK283542B6 (sk) 2003-09-11
CA2231535A1 (en) 1997-04-10
KR19990064013A (ko) 1999-07-26
PL328167A1 (en) 1999-01-18
BG63916B1 (bg) 2003-06-30
NO311024B1 (no) 2001-10-01
EP0888309A1 (en) 1999-01-07
DE69626862D1 (de) 2003-04-24
RO120409B1 (ro) 2006-01-30
LV12108B (en) 1998-10-20
BG102324A (en) 1999-01-29
US6479530B2 (en) 2002-11-12
US6313311B1 (en) 2001-11-06
RU2188194C2 (ru) 2002-08-27
IL123721A0 (en) 1998-10-30
SI9620111B (en) 2001-12-31
PL189110B1 (pl) 2005-06-30
NO981496D0 (no) 1998-04-02
ES2195013T3 (es) 2003-12-01
SK43998A3 (en) 1998-10-07
CZ291576B6 (cs) 2003-04-16
EP0888309B1 (en) 2003-03-19
DK0888309T3 (da) 2003-04-22
WO1997012874A1 (en) 1997-04-10
HUP9802927A2 (hu) 1999-10-28
UA49847C2 (uk) 2002-10-15
HK1014951A1 (en) 1999-10-08
EE9800101A (et) 1998-10-15
LT98057A (en) 1998-09-25
CN1198741A (zh) 1998-11-11
JP2000507914A (ja) 2000-06-27
EE04436B1 (et) 2005-02-15
LV12108A (lv) 1998-08-20
SI9620111A (sl) 1998-10-31
AU7132796A (en) 1997-04-28
NO981496L (no) 1998-04-02
US20020007074A1 (en) 2002-01-17

Similar Documents

Publication Publication Date Title
GB9520150D0 (en) New imidazole derivatives
FI20010083A (fi) P-reseptoriantagonistien synteesissä käytetyt välituotteet ja menetelmä niiden valmistamiseksi
HUT70513A (en) Piperazine derivatives as 5-ht receptors antagonists, pharmaceutical compositions comprising them and method for producing thereof
PL302163A1 (en) Novel derivatives of benzimidazolone
CA2401229A1 (en) Aryl fused azapolycyclic compounds
NZ331060A (en) Quinoxalinediones, preparation and pharmaceutical compositions thereof
MY136258A (en) 5-phenyl-pyrimidine derivatives
JO2261B1 (en) Derivatives 4 - Phenylbarmidine
DE69512208D1 (de) Aminosäurederivate und ihre verwendung als phospholipase-a2-inhibitoren
AP9801410A0 (en) Indoline derivatives useful as 5-HT-2C receptor antagonists.
FR2633292B1 (fr) Nouveaux derives de la 20,21-dinoreburnamenine substitues en 15 par un groupement amine, leur procede de preparation et les intermediaires ainsi obtenus, leur application comme medicaments et les compositions pharmaceutiques les reenfermant
TH48884A (th) อนุพันธ์ 4-ฟีนิล-ไพริมิดิน